Popular on Amzeal
- Human Resources Strategy Forum Celebrates 30 Years Empowering Leaders, Shaping the Next Generation of HR Innovators - 119
- Omnitronics Proud to Join NXDN Forum
- Legionnaire Awarded $3.19M AFWERX Contract to Develop Next Generation Air-refueling System
- Diana Partners With OpsVeda To Leverage AI-ML To Get Closer To Its Consumers
- Phishing Protection Industry Growth, Development and Forecast Report, 2030
- Allegiant Management Group Launches New Website Following Recent Rebranding
- E.G. Phillips Cinematic Single a Fiery Rebuke to Election Season Chaos Agents
- Ron Johnson Announced as the 39th Black Engineer of the Year
- Democracy at Work & The Left Forum Presents Seminar with Professor Richard D. Wolff based on "Understanding Capitalism"
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New Doctor of Behavioral Health Graduates
Similar on Amzeal
- CCHR Wants Increased Consumer Awareness About "Prescriptions for Violence"
- Nurturing Healthy Smiles Through Little Mouth Program
- Integris Composites Displays New Military Armor at AUSA 2024
- Cummings Graduate Institute for Behavioral Health Studies Announces New Book: Integrated Behavioral Health: Applying the Biodyne Mindset in Healthcare
- National Minority Health Association and Cell-Ed Announce Upcoming Webinar: Empowering Caregivers Through Innovative Training Programs
- NEMTAC Announces Public Comment Period for the NEMTAC 3001-202X Transportation Specialist Education Draft Standard
- Dr. Stephen Shainbart, PHD, Highlights 5 Reasons to Discuss Family Therapy and Couples Counseling in Buffalo, NY
- Purple Union C-Murder Supporting Angola Prisoners in Their Fight for Basic Human Rights Through Labor Strike
- Cell-Ed and National Minority Health Association Forge Strategic Partnership to Expand Caregiving and Health Equity Initiatives
- Fortius Metals secures $2 Million Additional Funding to Bring Advanced Metal 3D Printing to the Aerospace and Defense Industry
NeuraWorx Partners with Corundum Neuroscience to Initiate Clinical Feasibility Study, Develop Innovative Neurological Disease Treatment
Amzeal News/10573991
EXCELSIOR, Minn. - Amzeal -- NeuraWorx Medical Technologies, Inc., a neurotechnology therapeutics company, announced today a partnership with prominent neuroscience venture builder and fund, Corundum Neuroscience. As part of the collaboration, Corundum will provide resources, including the initial investment in a NeuraWorx seed funding round, aimed at advancing product development and initiating a clinical feasibility study to explore the efficacy and safety of its Cerebrovascular Pacing SystemTM novel technology.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
More on Amzeal News
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
More on Amzeal News
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
More on Amzeal News
- Nurturing Healthy Smiles Through Little Mouth Program
- Experience the Future of Digital Textbook with KITABOO at FBF 2024 and Win an iPad Daily!
- Integris Composites Displays New Military Armor at AUSA 2024
- Expert HVAC Upgrade Tips to Maximize Energy Efficiency
- Ledger Wallet: The Secure Crypto Storage Solution Every Investor Needs Today
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
More on Amzeal News
- ALLTRA SmartChain Partners with Kryptobox.io to Enhance Global Digital Asset Accessibility
- ALLTRA SonicSwap Expands DeFi Opportunities with Weekly Listings and Global Partnerships
- ALL Mainnet Launches AUSDT Stablecoin onto the global arena
- Alana Winns Steps Down as Editor-in-Chief and Chief Content Officer of Career Communications Group
- The Giving Edge: Is Leveraging Outrageous Kindness the Missing Link for Corporate ROI?
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
Source: NeuraWorx Medical Technologies, Inc.
0 Comments
Latest on Amzeal News
- Invenio IT Partners with Vonahi Security to Offer Automated Network Penetration Testing for Enhanced Security
- National Minority Health Association and Cell-Ed Announce Upcoming Webinar: Empowering Caregivers Through Innovative Training Programs
- ASI Launches 2025 iMISĀ® Membership Benchmark Survey; Open Until October 31
- Cyber Safe Institute Hosts Landmark AI Quantum Cybersecurity Career Fair at NIST Cybersecurity Week
- Free 6-Month Premium Matrimonial Membership Now Available on IndoMarry.com
- NEMTAC Announces Public Comment Period for the NEMTAC 3001-202X Transportation Specialist Education Draft Standard
- Dr. Stephen Shainbart, PHD, Highlights 5 Reasons to Discuss Family Therapy and Couples Counseling in Buffalo, NY
- Restoration Specialists Celebrates a Successful 2024 and Strong Q4
- Purple Union C-Murder Supporting Angola Prisoners in Their Fight for Basic Human Rights Through Labor Strike
- Secure Life App Launches: A Revolutionary Health and Safety Platform for You and Your Loved Ones
- NetverseAI and NetaverseAI By Phinge Will Be The Safest and Only Verified AI In The World
- OpsVeda Is Now Available Through AWS Marketplace
- Circumference Group Acquires Majority Stake in Visionary Integration Professionals
- Tim O'Loughlin Appointed Chief Executive Officer of Vantiva and Co-opted as a Director of the Board
- TN Nursery Gears Up for Busy Fall Shipping Season with Nationwide Fast Shipping, Low Grower Prices, and Storewide Deals
- Energy Psychology Group Announces Conclusion of Strategic Alliance with Cosmic Media
- Jazz Artist Bob Holz Signs With SoVibe Entertainment Plus Album Review In September 2024 Issue Of Downbeat Magazine
- Develop Africa Partners with Sierra Leonean Painter Sahr Songu Mbriwa to Raise Funds for Education
- Composer Andrew Prahlow to Perform Award-Winning Outer Wilds Soundtrack on Oct 17th at Brooklyn's Music Hall of Williamsburg
- CostPredict Inc. Accepted for Participation in an Exclusive Tech Venture Accelerator Program